Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer - PubMed (original) (raw)

Review

doi: 10.1038/nrc1779.

Affiliations

Free article

Review

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Saverio Minucci et al. Nat Rev Cancer. 2006 Jan.

Free article

Abstract

Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clinical trials. A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved. However, several basic aspects are not yet fully understood. Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clinical protocols.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources